Rhoen Klinikum (ETR: RHK) has recently received a number of price target changes and ratings updates:
5/14/2018 – Rhoen Klinikum was given a new €29.15 ($34.70) price target on by analysts at Berenberg Bank. They now have a “neutral” rating on the stock. 5/8/2018 – Rhoen Klinikum was given a new €29.00 ($34.52) price target on by analysts at Independent Research GmbH. They now have a “neutral” rating on the stock. 5/4/2018 – Rhoen Klinikum was given a new €22.00 ($26.19) price target on by analysts at Kepler Capital Markets. They now have a “sell” rating on the stock. 5/4/2018 – Rhoen Klinikum was given a new €25.20 ($30.00) price target on by analysts at Warburg Research. They now have a “neutral” rating on the stock. 4/4/2018 – Rhoen Klinikum was given a new €25.20 ($30.00) price target on by analysts at Warburg Research. They now have a “neutral” rating on the stock. 4/3/2018 – Rhoen Klinikum was given a new €29.00 ($34.52) price target on by analysts at Independent Research GmbH. They now have a “neutral” rating on the stock. 3/29/2018 – Rhoen Klinikum was given a new €25.20 ($30.00) price target on by analysts at Warburg Research. They now have a “neutral” rating on the stock.
Shares of Rhoen Klinikum stock opened at €26.60 ($31.67) on Friday. Rhoen Klinikum AG has a 1-year low of €25.08 ($29.86) and a 1-year high of €32.12 ($38.24).
RH�N-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services primarily in the areas of cardiovascular, neurological disorders, oncology, pneumology, orthopedic, accident, and surgeries; rehabilitation and nursing services to the elderly; and thoracic, tumors, and psychosomatic, as well as spinal, column, and joints diseases.
No comments:
Post a Comment